# Phase 3 Multiple Myeloma trials recruiting: 57 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 57 trials in phase 3 for Multiple Myeloma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 Multiple Myeloma trials: 57 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/multiple-myeloma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 57
- Recruiting or not yet: 57
- Read on: November 19, 2026

## Trials

The 25 newest of 57, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07933432 | A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131 | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Relapsed or Refractory Multiple Myeloma | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07933432) |
| November 2, 2026 | NCT07910903 | Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma | Keymed Biosciences Co.Ltd | Phase 3 | Not yet recruiting | Multiple Myeloma (MM) | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07910903) |
| October 29, 2026 | NCT07903506 | To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma | Kite, A Gilead Company | Phase 3 | Not yet recruiting | Newly Diagnosed Multiple Myeloma | 750 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903506) |
| October 29, 2026 | NCT07903272 | A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants... | Janssen Research & Development, LLC | Phase 3 | Not yet recruiting | Multiple Myeloma | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903272) |
| October 21, 2026 | NCT07887672 | A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma | Kite, A Gilead Company | Phase 3 | Not yet recruiting | Newly Diagnosed Multiple Myeloma | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07887672) |
| August 14, 2026 | NCT07764978 | Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT | AstraZeneca | Phase 3 | Recruiting | Newly Diagnosed Multiple Myeloma | 750 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07764978) |
| August 3, 2026 | NCT07742215 | A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma... | Biocad | Phase 3 | Recruiting | Myeloma Multiple | 390 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07742215) |
| July 31, 2026 | NCT07740486 | A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After... | Polish Myeloma Consortium | Phase 3 | Not yet recruiting | Multiple Myeloma (MM) | 248 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07740486) |
| July 30, 2026 | NCT07735637 | A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed... | AstraZeneca | Phase 3 | Recruiting | Newly Diagnosed Multiple Myeloma (NDMM) | 750 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07735637) |
| July 27, 2026 | NCT07728188 | A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies... | AbbVie | Phase 3 | Recruiting | Relapsed or Refractory Multiple Myeloma | 520 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07728188) |
| June 26, 2026 | NCT07671287 | GMMG-HD11/DSMM XXI/64007957MMY3010 | University of Heidelberg Medical Center | Phase 3 | Not yet recruiting | Multiple Myeloma | 399 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07671287) |
| June 24, 2026 | NCT07665450 | A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide... | Janssen Research & Development, LLC | Phase 3 | Recruiting | Multiple Myeloma | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07665450) |
| June 16, 2026 | NCT07649525 | Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level | University of Leeds | Phase 3 | Recruiting | Multiple Myeloma (MM), Plasma Cell Leukemia (PCL) | 1,226 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07649525) |
| June 15, 2026 | NCT07648264 | Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting... | CSL Behring | Phase 3 | Recruiting | Secondary Immune Deficiency | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07648264) |
| June 3, 2026 | NCT07624513 | D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM | Dana-Farber Cancer Institute | Phase 3 | Recruiting | Multiple Myeloma | 720 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07624513) |
| June 3, 2026 | NCT07623798 | A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 3 | Recruiting | Relapsed or Refractory Multiple Myeloma | 255 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623798) |
| May 12, 2026 | NCT07582432 | A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency... | Grifols Biologicals, LLC | Phase 3 | Recruiting | Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07582432) |
| May 12, 2026 | NCT07579234 | A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety... | Shandong New Time Pharmaceutical Co., LTD | Phase 3 | Recruiting | Relapsed or Refractory Multiple Myeloma (RRMM) | 261 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07579234) |
| May 6, 2026 | NCT07569757 | Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 3 | Not yet recruiting | Multiple Myeloma | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07569757) |
| April 29, 2026 | NCT07555938 | Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple... | Hoffmann-La Roche | Phase 3 | Recruiting | Multiple Myeloma | 380 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07555938) |
| April 8, 2026 | NCT07518186 | A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma | Janssen Research & Development, LLC | Phase 3 | Recruiting | Multiple Myeloma | 700 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07518186) |
| March 5, 2026 | NCT07452198 | A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple... | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 3 | Recruiting | Multiple Myeloma | 358 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07452198) |
| February 17, 2026 | NCT07413809 | Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen | The Affiliated People's Hospital of Ningbo University | Phase 3 | Recruiting | Multiple Myeloma | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07413809) |
| February 6, 2026 | NCT07393282 | A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) | Regeneron Pharmaceuticals | Phase 3 | Recruiting | High Risk Smoldering Multiple Myeloma (HR-SMM) | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07393282) |
| February 6, 2026 | NCT07391657 | A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in... | AstraZeneca | Phase 3 | Recruiting | Relapsed Refractory Multiple Myeloma | 508 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07391657) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Janssen Research & Development, LLC](https://specstream.ai/data/clinical-trials/company/janssen-research-and-development-llc) | 5 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 3 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 3 |
| [Qilu Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/qilu-pharmaceutical-co-ltd) | 3 |
| [Keymed Biosciences Co.Ltd](https://specstream.ai/data/clinical-trials/company/keymed-biosciences-co-ltd) | 2 |
| University of Leeds | 2 |
| ECOG-ACRIN Cancer Research Group | 2 |
| [Kite, A Gilead Company](https://specstream.ai/data/clinical-trials/company/kite-a-gilead-company) | 2 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 2 |
| The Affiliated People's Hospital of Ningbo University | 2 |
| [Genrix (Shanghai) Biopharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/genrix-shanghai-biopharmaceutical-co-ltd) | 1 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 1 |
| PrECOG, LLC. | 1 |
| Dana-Farber Cancer Institute | 1 |
| Canadian Cancer Trials Group | 1 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 1 |
| [Innovent Biologics (Suzhou) Co. Ltd.](https://specstream.ai/data/clinical-trials/company/innovent-biologics-suzhou-co-ltd) | 1 |
| [Celgene](https://specstream.ai/data/clinical-trials/company/celgene) | 1 |
| SWOG Cancer Research Network | 1 |
| [Chia Tai Tianqing Pharmaceutical Group Co., Ltd.](https://specstream.ai/data/clinical-trials/company/chia-tai-tianqing-pharmaceutical-group-co-ltd) | 1 |
| Polish Myeloma Consortium | 1 |
| Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 1 |
| St. Louis University | 1 |
| [Sinocelltech Ltd.](https://specstream.ai/data/clinical-trials/company/sinocelltech-ltd) | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 27 |
| China | 23 |
| France | 19 |
| United Kingdom | 19 |
| Italy | 18 |
| Spain | 18 |
| Australia | 17 |
| Germany | 17 |
| Canada | 17 |
| Poland | 16 |
| Japan | 16 |
| South Korea | 15 |
| Brazil | 15 |
| Czechia | 13 |
| Greece | 13 |
| Israel | 13 |
| Netherlands | 11 |
| Taiwan | 11 |
| Belgium | 10 |
| Norway | 10 |
| Denmark | 9 |
| Turkey (Türkiye) | 8 |
| Austria | 7 |
| Portugal | 6 |
| Argentina | 6 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Equipment rental companies in the United States](https://specstream.ai/data/businesses/equipment-rental-companies/united-states)
- [Hot dog restaurants in the United States](https://specstream.ai/data/businesses/hot-dog-restaurants/united-states)
- [Medical sciences schools in the United States](https://specstream.ai/data/businesses/medical-sciences-schools/united-states)
- [Polynesian restaurants in the United States](https://specstream.ai/data/businesses/polynesian-restaurants/united-states)
- [Speech training companies in the United States](https://specstream.ai/data/businesses/speech-training-companies/united-states)
- [Wholesale florists in the United States](https://specstream.ai/data/businesses/wholesale-florists/united-states)
